Bristol Sprycel Cardiovascular Issues Not Enough To Prevent Accelerated Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
QT prolongation appears to have been one of the primary safety considerations during FDA’s review of Bristol-Myers Squibb’s leukemia treatment Sprycel (dasatinib), review documents suggest.